Shares of Smith & Nephew plc (LON:SN – Get Free Report) have earned an average recommendation of “Hold” from the nine ratings firms that are covering the stock, MarketBeat.com reports. Six investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is GBX 1,242.50.
Several equities research analysts recently issued reports on the stock. Berenberg Bank cut their target price on shares of Smith & Nephew from GBX 1,300 to GBX 1,250 and set a “hold” rating for the company in a research note on Friday, August 14th. Royal Bank Of Canada lowered their price target on Smith & Nephew from GBX 1,350 to GBX 1,250 and set a “sector perform” rating on the stock in a research report on Thursday, August 6th. Shore Capital Group reissued a “buy” rating and set a GBX 1,000 price target on shares of Smith & Nephew in a research report on Tuesday, July 21st. Jefferies Financial Group dropped their price objective on Smith & Nephew from GBX 1,500 to GBX 1,400 and set a “buy” rating on the stock in a research note on Thursday, November 5th. Finally, Deutsche Bank reaffirmed a “hold” rating and issued a GBX 1,250 price objective on shares of Smith & Nephew in a research report on Tuesday, September 15th.
Get Our Latest Research Report on SN
Smith & Nephew Price Performance
Smith & Nephew stock opened at GBX 1,138.50 on Thursday. The firm has a market cap of £12.48 billion, a price-to-earnings ratio of 40.99, a PEG ratio of 0.46 and a beta of 0.69. The business’s fifty day moving average price is GBX 1,063.34 and its 200-day moving average price is GBX 1,150.59. The company has a quick ratio of 0.84, a current ratio of 2.14 and a debt-to-equity ratio of 73.07.
About Smith & Nephew
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.
See Also
- Five stocks we like better than Smith & Nephew
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.
